Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 51
Filtrar
3.
Europace ; 20(5): 851-858, 2018 05 01.
Artigo em Inglês | MEDLINE | ID: mdl-28387796

RESUMO

Aims: Coronary artery spasm (CAS) is associated with ventricular arrhythmias (VA). Much controversy remains regarding the best therapeutic interventions for this specific patient subset. We aimed to evaluate the clinical outcomes of patients with a history of life-threatening VA due to CAS with various medical interventions, as well as the need for ICD placement in the setting of optimal medical therapy. Methods and results: A multicentre European retrospective survey of patients with VA in the setting of CAS was aggregated and relevant clinical and demographic data was analysed. Forty-nine appropriate patients were identified: 43 (87.8%) presented with VF and 6 (12.2%) with rapid VT. ICD implantation was performed in 44 (89.8%). During follow-up [59 (17-117) months], appropriate ICD shocks were documented in 12. In 8/12 (66.6%) no more ICD therapies were recorded after optimizing calcium channel blocker (CCB) therapy. SCD occurred in one patient without ICD. Treatment with beta-blockers was predictive of appropriate device discharge. Conversely, non-dihydropyridine CCB therapy was significantly protective against VAs. Conclusion: Patients with life-threatening VAs secondary to CAS are at particularly high-risk for recurrence, especially when insufficient medical therapy is administered. Non-dihydropyridine CCBs are capable of suppressing episodes, whereas beta-blocker treatment is predictive of VAs. Ultimately, in spite of medical intervention, some patients exhibited arrhythmogenic events in the long-term, suggesting that ICD implantation may still be indicated for all.


Assuntos
Antagonistas Adrenérgicos beta/uso terapêutico , Bloqueadores dos Canais de Cálcio/uso terapêutico , Vasoespasmo Coronário , Morte Súbita Cardíaca , Efeitos Adversos de Longa Duração , Fibrilação Ventricular , Vasoespasmo Coronário/complicações , Vasoespasmo Coronário/tratamento farmacológico , Morte Súbita Cardíaca/etiologia , Morte Súbita Cardíaca/prevenção & controle , Desfibriladores Implantáveis/estatística & dados numéricos , Europa (Continente)/epidemiologia , Feminino , Humanos , Efeitos Adversos de Longa Duração/diagnóstico , Efeitos Adversos de Longa Duração/prevenção & controle , Masculino , Recidiva , Estudos Retrospectivos , Medição de Risco , Prevenção Secundária/métodos , Fibrilação Ventricular/diagnóstico , Fibrilação Ventricular/etiologia , Fibrilação Ventricular/mortalidade , Fibrilação Ventricular/terapia
9.
Rev. esp. cardiol. (Ed. impr.) ; 69(11): 1033-1041, nov. 2016. graf, tab
Artigo em Espanhol | IBECS | ID: ibc-157509

RESUMO

Introducción y objetivos: Se han elaborado varias puntuaciones clínicas del riesgo para identificar a los pacientes con un riesgo de mortalidad por cualquier causa elevado a pesar del implante de un desfibrilador implantable. El objetivo de este trabajo es examinar y comparar la capacidad predictiva de 4 sistemas de puntuación sencillos (MADIT-II, FADES, PACE y SHOCKED) por lo que respecta a la predicción de la mortalidad tras implante de desfibrilador para la prevención primaria de la muerte súbita cardiaca en un país mediterráneo. Métodos: Se llevó a cabo un estudio multicéntrico retrospectivo en 15 hospitales españoles. Se incluyó a los pacientes consecutivos remitidos para implante de desfibrilador entre enero de 2010 y diciembre de 2011. Resultados: Se incluyó a 916 pacientes con cardiopatía isquémica o no isquémica (media de edad, 62 ± 11 años; el 81,4% varones). Durante un periodo de 33,4 ± 12,9 meses, fallecieron 113 pacientes (12,3%), el 9,4% (86 pacientes) por causa cardiovascular. A los 12, 24, 36 y 48 meses, la tasa de mortalidad fue del 4,5, el 7,6, el 10,8 y el 12,3% respectivamente. Todas las puntuaciones de riesgo mostraron un aumento escalonado del riesgo de muerte a lo largo de todo el sistema de puntuación de cada una de ellas y las 4 identificaron a los pacientes en mayor riesgo de mortalidad. Las puntuaciones tuvieron asociación significativa con la mortalidad por cualquier causa en todo el periodo de seguimiento. La puntuación PACE fue la que mostró un valor del índice c más bajo, tanto si la población tenía una cardiopatía de origen isquémico (estadístico c = 0,61) como si era de origen no isquémico (estadístico c = 0,61), mientras que la puntuación MADIT-II (estadístico c = 0,67 y 0,65 en la miocardiopatía isquémica y no isquémica respectivamente), las puntuaciones SHOCKED (estadístico c = 0,68 y 0,66 respectivamente) y FADES (estadístico c = 0,66 y 0,60) mostraron unos valores del estadístico c similares (p ≥ 0,09). Conclusiones: En esta cohorte de pacientes mediterráneos que no formaba parte de un ensayo clínico, las 4 puntuaciones de riesgo evaluadas mostraron un significativo aumento escalonado del riesgo de muerte. De entre las puntuaciones de riesgo existentes, MADIT-II, FADES y SHOCKED aportan un rendimiento ligeramente superior al de la puntuación PACE (AU)


Introduction and objectives: Several clinical risk scores have been developed to identify patients at high risk of all-cause mortality despite implantation of an implantable cardioverter-defibrillator. We aimed to examine and compare the predictive capacity of 4 simple scoring systems (MADIT-II, FADES, PACE and SHOCKED) for predicting mortality after defibrillator implantation for primary prevention of sudden cardiac death in a Mediterranean country. Methods: A multicenter retrospective study was performed in 15 Spanish hospitals. Consecutive patients referred for defibrillator implantation between January 2010 and December 2011 were included. Results: A total of 916 patients with ischemic and nonischemic heart disease were included (mean age, 62 ± 11 years, 81.4% male). Over 33.4 ± 12.9 months, 113 (12.3%) patients died (cardiovascular origin in 86 [9.4%] patients). At 12, 24, 36, and 48 months, mortality rates were 4.5%, 7.6%, 10.8%, and 12.3% respectively. All the risk scores showed a stepwise increase in the risk of death throughout the scoring system of each of the scores and all 4 scores identified patients at greater risk of mortality. The scores were significantly associated with all-cause mortality throughout the follow-up period. PACE displayed the lowest c-index value regardless of whether the population had heart disease of ischemic (c-statistic = 0.61) or nonischemic origin (c-statistic = 0.61), whereas MADIT-II (c-statistic = 0.67 and 0.65 in ischemic and nonischemic cardiomyopathy, respectively), SHOCKED (c-statistic = 0.68 and 0.66, respectively), and FADES (c-statistic = 0.66 and 0.60) provided similar c-statistic values (P ≥ .09). Conclusions: In this nontrial-based cohort of Mediterranean patients, the 4 evaluated risk scores showed a significant stepwise increase in the risk of death. Among the currently available risk scores, MADIT-II, FADES, and SHOCKED provide slightly better performance than PACE (AU)


Assuntos
Humanos , Cardioversão Elétrica/mortalidade , Desfibriladores Implantáveis/estatística & dados numéricos , Morte Súbita Cardíaca/epidemiologia , Cardiomiopatias/mortalidade , Prevenção Primária/métodos , Risco Ajustado/métodos , Fatores de Risco , Estudos Retrospectivos , Reprodutibilidade dos Testes
10.
Rev Esp Cardiol (Engl Ed) ; 69(11): 1033-1041, 2016 Nov.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-27491594

RESUMO

INTRODUCTION AND OBJECTIVES: Several clinical risk scores have been developed to identify patients at high risk of all-cause mortality despite implantation of an implantable cardioverter-defibrillator. We aimed to examine and compare the predictive capacity of 4 simple scoring systems (MADIT-II, FADES, PACE and SHOCKED) for predicting mortality after defibrillator implantation for primary prevention of sudden cardiac death in a Mediterranean country. METHODS: A multicenter retrospective study was performed in 15 Spanish hospitals. Consecutive patients referred for defibrillator implantation between January 2010 and December 2011 were included. RESULTS: A total of 916 patients with ischemic and nonischemic heart disease were included (mean age, 62 ± 11 years, 81.4% male). Over 33.4 ± 12.9 months, 113 (12.3%) patients died (cardiovascular origin in 86 [9.4%] patients). At 12, 24, 36, and 48 months, mortality rates were 4.5%, 7.6%, 10.8%, and 12.3% respectively. All the risk scores showed a stepwise increase in the risk of death throughout the scoring system of each of the scores and all 4 scores identified patients at greater risk of mortality. The scores were significantly associated with all-cause mortality throughout the follow-up period. PACE displayed the lowest c-index value regardless of whether the population had heart disease of ischemic (c-statistic = 0.61) or nonischemic origin (c-statistic = 0.61), whereas MADIT-II (c-statistic = 0.67 and 0.65 in ischemic and nonischemic cardiomyopathy, respectively), SHOCKED (c-statistic = 0.68 and 0.66, respectively), and FADES (c-statistic = 0.66 and 0.60) provided similar c-statistic values (P ≥ .09). CONCLUSIONS: In this nontrial-based cohort of Mediterranean patients, the 4 evaluated risk scores showed a significant stepwise increase in the risk of death. Among the currently available risk scores, MADIT-II, FADES, and SHOCKED provide slightly better performance than PACE.


Assuntos
Morte Súbita Cardíaca/prevenção & controle , Desfibriladores Implantáveis , Cardiopatias/terapia , Mortalidade , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Fibrilação Atrial/epidemiologia , Causas de Morte , Creatinina/sangue , Morte Súbita Cardíaca/etiologia , Diabetes Mellitus/epidemiologia , Cardioversão Elétrica , Feminino , Cardiopatias/complicações , Cardiopatias/epidemiologia , Humanos , Masculino , Pessoa de Meia-Idade , Prevenção Primária , Modelos de Riscos Proporcionais , Insuficiência Renal Crônica/sangue , Insuficiência Renal Crônica/epidemiologia , Estudos Retrospectivos , Medição de Risco , Fumar/epidemiologia , Espanha/epidemiologia , Volume Sistólico
11.
Rev. urug. cardiol ; 31(1): 176-184, abr. 2016. tab
Artigo em Espanhol | LILACS-Express | ID: lil-789153

RESUMO

Introducción: la ablación de la fibrilación auricular es uno de los procedimientos más frecuentemente realizados en las unidades de arritmias. La información de los resultados proviene de estudios prospectivos, registros multicéntricos y registros nacionales. Objetivo: evaluar la situación de la ablación de la fibrilación auricular en España a través de los datos recogidos en el Registro Español de Ablación, auspiciado por la Sección de Electrofisiología y Arritmias de la Sociedad Española de Cardiología. Métodos: los datos analizados provienen de los formularios remitidos, de forma voluntaria y anónima, por los diferentes centros hospitalarios, tanto de financiación pública como privada, durante el período 2008-2013. Cada centro fue analizado, año a año, de forma independiente. Analizamos los recursos humanos y materiales de los centros que realizaron procedimientos de ablación de fibrilación auricular durante ese período de tiempo. Asimismo, analizamos la técnica utilizada, el tipo de energía, complicaciones, etcétera. Comparamos todas las variables de forma evolutiva, año a año. Dividimos a los centros en función del número de procedimientos de ablación realizados cada año: 1-49, grupo A; 50-99, grupo B, y 100 o más, grupo C. Resultados: trescientos noventa y un centros (n=391) y 8.926 procedimientos de ablación fueron analizados. Año a año ha aumentado el número de centros que realizan ablación de fibrilación auricular y el número de procedimientos que realiza cada centro. El porcentaje de complicaciones se ha mantenido estable reduciéndose ligeramente la mortalidad. Los centros con mayor volumen tienen mayor dotación de recursos humanos y materiales. Realizan ablación de fibrilación auricular persistente con mayor frecuencia y realizan crioablación con menor frecuencia. Asimismo, estos centros tienen una menor incidencia de complicaciones. Conclusiones: la ablación de fibrilación auricular en España ha aumentado en los últimos años y presenta resultados similares a los recogidos en otros registros nacionales y multinacionales.

12.
Rev. esp. cardiol. (Ed. impr.) ; 69(3): 272-278, mar. 2016. tab, graf
Artigo em Espanhol | IBECS | ID: ibc-151950

RESUMO

Introducción y objetivos: Existe escasa evidencia sobre la evolución de los pacientes con miocardiopatía valvular remitidos para implante de desfibrilador por prevención primaria. Se pretende describir la evolución de este subgrupo particular. Métodos: Estudio multicéntrico retrospectivo en 15 centros españoles que incluyó pacientes consecutivos remitidos para implante de desfibrilador en los años 2010 y 2011, y en tres centros desde el 1 enero de 2008. Resultados: De un total de 1.174 pacientes, 73 (6,2%) presentaron miocardiopatía valvular. Comparados con los pacientes con miocardiopatía isquémica (n = 659; 56,1%) o dilatada (n = 442; 37,6%), presentaron peor clase funcional, mayor anchura del QRS y antecedente de fibrilación auricular. Durante un seguimiento de 38,1 ± 21,3 meses, 197 (16,7%) pacientes fallecieron por cualquier causa, sin diferencias significativas entre grupos (19,2% en miocardiopatía valvular, 15,8% en isquémica y 17,9% en miocardiopatía dilatada; p = 0,2). De estos, 136 murieron por causa cardiovascular (11,6%), sin diferencias significativas (12,3%; 10,5% y 13,1%, respectivamente; p = 0,1). Tampoco hubo diferencias en la proporción de intervenciones apropiadas del desfibrilador (13,7%; 17,9% y 18,8%; p = 0,4), pero sí en el de inapropiadas (8,2%; 7,1% y 12,0%, respectivamente; p = 0,03). Conclusiones: Las tasas de mortalidad por cualquier causa y por causa cardiovascular en pacientes con miocardiopatía valvular fueron similares a las del resto de los pacientes remitidos para implante de desfibrilador. También presentaron similares tasas de intervenciones apropiadas. Estos datos parecen indicar que el implante de un desfibrilador en este grupo confiere un beneficio similar al que obtienen los pacientes con miocardiopatía isquémica y miocardiopatía dilatada (AU)


Introduction and objectives: Few data exist on the outcomes of valvular cardiomyopathy patients referred for defibrillator implantation for primary prevention. The aim of the present study was to describe the outcomes of this cardiomyopathy subgroup. Methods: This multicenter retrospective study included consecutive patients referred for defibrillator implantation to 15 Spanish centers in 2010 and 2011, and to 3 centers after 1 January 2008. Results: Of 1174 patients, 73 (6.2%) had valvular cardiomyopathy. These patients had worse functional class, wider QRS, and a history of atrial fibrillation vs patients with ischemic (n = 659; 56.1%) or dilated (n = 442; 37.6%) cardiomyopathy. During a follow-up of 38.1 ± 21.3 months, 197 patients (16.7%) died, without significant differences among the groups (19.2% in the valvular cardiomyopathy group, 15.8% in the ischemic cardiomyopathy group, and 17.9% in the dilated cardiomyopathy group; P = .2); 136 died of cardiovascular causes (11.6%), without significant differences among the groups (12.3%, 10.5%, and 13.1%, respectively; P = .1). Although there were no differences in the proportion of appropriate defibrillator interventions (13.7%, 17.9%, and 18.8%; P = .4), there was a difference in inappropriate interventions (8.2%, 7.1%, and 12.0%, respectively; P = .03). Conclusions: All-cause and cardiovascular mortality in patients with valvular cardiomyopathy were similar to those in other patients referred for defibrillator implantation. They also had similar rates of appropriate interventions. These data suggest that defibrillator implantation in this patient group confers a similar benefit to that obtained by patients with ischemic or dilated cardiomyopathy (AU)


Assuntos
Humanos , Doenças das Valvas Cardíacas/complicações , Morte Súbita Cardíaca/prevenção & controle , Cardioversão Elétrica , Desfibriladores Implantáveis , Prevenção Primária/métodos , Avaliação de Resultado de Intervenções Terapêuticas , Fatores de Risco
13.
Pacing Clin Electrophysiol ; 39(1): 73-80, 2016 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-26450114

RESUMO

BACKGROUND: We sought to assess the efficacy of high-energy shocks to restore rhythm and predictors of success in patients with sustained ventricular arrhythmias and implantable cardioverter defibrillator (ICD). METHODS AND RESULTS: Data from 162 patients included in the UMBRELLA study that experienced one or more episodes of ventricular tachycardia (VT) for which ICD shocks of at least 30 Joules were delivered (appropriate high-energy shocks) were analyzed. In total, 456 ventricular arrhythmia episodes were registered. Forty four episodes (9.6%) from 39 patients (24%) had at least one ineffective high-energy shock delivered. Hypertrophic cardiomyopathy was more frequent among patients with unsuccessful shocks (10.3% vs 2.4%). Patients with ineffective shocks had higher proportion of sustained monomorphic ventricular arrhythmias (86.4%; the other 13.6% were sustained polymorphic and ventricular fibrillation [VF]) compared with patients with all their shocks effective (62.9%, P = 0.02). No statistical differences were found between groups in time from detection to the high-energy shock delivery, in tachycardia cycle length, or in antitachycardia pacing, but patients with ineffective high-energy shocks had higher proportion of previously ineffective low-energy shock (9.1% vs 0.5%, P = 0.01). CONCLUSION: We found a substantial rate of ineffective high-energy shocks for the treatment of VT or VF in patients with ICD. High-energy shock efficacy seems to be reduced by hypertrophic cardiomyopathy and by the administration of previous low-energy shocks.


Assuntos
Desfibriladores Implantáveis/estatística & dados numéricos , Taquicardia Ventricular/mortalidade , Taquicardia Ventricular/prevenção & controle , Terapia Assistida por Computador/estatística & dados numéricos , Fibrilação Ventricular/mortalidade , Fibrilação Ventricular/prevenção & controle , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Prevalência , Reprodutibilidade dos Testes , Fatores de Risco , Sensibilidade e Especificidade , Espanha/epidemiologia , Taxa de Sobrevida , Terapia Assistida por Computador/métodos , Resultado do Tratamento
14.
Rev Esp Cardiol (Engl Ed) ; 69(3): 272-8, 2016 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-26481284

RESUMO

INTRODUCTION AND OBJECTIVES: Few data exist on the outcomes of valvular cardiomyopathy patients referred for defibrillator implantation for primary prevention. The aim of the present study was to describe the outcomes of this cardiomyopathy subgroup. METHODS: This multicenter retrospective study included consecutive patients referred for defibrillator implantation to 15 Spanish centers in 2010 and 2011, and to 3 centers after 1 January 2008. RESULTS: Of 1174 patients, 73 (6.2%) had valvular cardiomyopathy. These patients had worse functional class, wider QRS, and a history of atrial fibrillation vs patients with ischemic (n=659; 56.1%) or dilated (n=442; 37.6%) cardiomyopathy. During a follow-up of 38.1 ± 21.3 months, 197 patients (16.7%) died, without significant differences among the groups (19.2% in the valvular cardiomyopathy group, 15.8% in the ischemic cardiomyopathy group, and 17.9% in the dilated cardiomyopathy group; P=.2); 136 died of cardiovascular causes (11.6%), without significant differences among the groups (12.3%, 10.5%, and 13.1%, respectively; P=.1). Although there were no differences in the proportion of appropriate defibrillator interventions (13.7%, 17.9%, and 18.8%; P=.4), there was a difference in inappropriate interventions (8.2%, 7.1%, and 12.0%, respectively; P=.03). CONCLUSIONS: All-cause and cardiovascular mortality in patients with valvular cardiomyopathy were similar to those in other patients referred for defibrillator implantation. They also had similar rates of appropriate interventions. These data suggest that defibrillator implantation in this patient group confers a similar benefit to that obtained by patients with ischemic or dilated cardiomyopathy.


Assuntos
Cardiomiopatia Dilatada/terapia , Morte Súbita Cardíaca/prevenção & controle , Doenças das Valvas Cardíacas/terapia , Isquemia Miocárdica/terapia , Idoso , Cardiomiopatias/complicações , Cardiomiopatias/terapia , Cardiomiopatia Dilatada/complicações , Estudos de Casos e Controles , Estudos de Coortes , Morte Súbita Cardíaca/etiologia , Desfibriladores Implantáveis , Feminino , Doenças das Valvas Cardíacas/complicações , Humanos , Masculino , Pessoa de Meia-Idade , Isquemia Miocárdica/complicações , Prevenção Primária , Modelos de Riscos Proporcionais , Implantação de Prótese , Estudos Retrospectivos
17.
Rev. esp. cardiol. (Ed. impr.) ; 66(12): 983-992, dic. 2013. tab, ilus
Artigo em Espanhol | IBECS | ID: ibc-117104

RESUMO

Introducción y objetivos. Se detallan los resultados del Registro Nacional de Ablación del año 2012. Métodos. La recogida de datos se llevó a cabo mediante dos sistemas. De manera retrospectiva con la cumplimentación de un formulario y de manera prospectiva a través de una base de datos común. La elección de una u otra fue voluntaria para cada uno de los centros. Resultados. Se recogieron datos de 74 centros. El número total de procedimientos de ablación fue 11.042, con una media de 149 ± 103 procedimientos. Los tres sustratos abordados con más frecuencia fueron la taquicardia intranodular (n = 2.842; 25,7%), la ablación del istmo cavotricuspídeo (n = 2.485; 23%) y las vías accesorias (n = 1.999; 18%). El cuarto sustrato fue la ablación de fibrilación auricular (n = 1.852; 17%), que mostró un incremento del 21% con respecto a los datos de 2011. La ablación de arritmias ventriculares ha permanecido estable, pero han disminuido los procedimientos sobre las asociadas a cicatriz tras infarto. La tasa total de éxito fue del 94,9%; la de complicaciones mayores, del 1,9% y la de mortalidad, del 0,04%. Conclusiones. El registro del año 2012 mantiene una línea de continuidad ascendente en el número de ablaciones realizadas y muestran, en líneas generales, una elevada tasa de éxito y bajo número de complicaciones. Continúa el aumento del abordaje de sustratos más complejos, especialmente de la fibrilación auricular (AU)


Introduction and objectives. This article presents the findings of the 2012 Spanish Catheter Ablation Registry. Methods. Data were collected in 2 ways: retrospectively using a standardized questionnaire, and prospectively using a central database. Each participating center selected its own preferred method of data collection. Results. Seventy-four Spanish centers voluntarily contributed data to the survey. A total of 11 042 ablation procedures were analyzed, averaging 149 (103) per center. The 3 main conditions treated were atrioventricular nodal reentrant tachycardia (n=2842; 25.7%), cavotricuspid isthmus (n=2485; 23%), and accessory pathways (n=1999; 18%). Atrial fibrillation was the fourth most common substrate treated (n=1852; 17%), representing a slight increase. The number of ventricular arrhythmia ablation procedures was similar to that of 2011, but there was a decrease in procedures for ventricular tachycardia associated with postinfarction scarring. The overall success rate was 94.9%, major complications occurred in 1.9%, and the overall mortality rate was 0.04%. Conclusions. Data from the 2012 registry show that the number of ablations performed continued to increase. Overall, they also show a high success rate and a low number of complications. Ablation of complex substrates continued to increase, particularly in the case of atrial fibrillation (AU)


Assuntos
Humanos , Masculino , Feminino , Ablação por Cateter/métodos , Ablação por Cateter , Eletrofisiologia Cardíaca/instrumentação , Eletrofisiologia Cardíaca/organização & administração , Arritmias Cardíacas/epidemiologia , Arritmias Cardíacas/prevenção & controle , Fibrilação Atrial/epidemiologia , Fibrilação Atrial/prevenção & controle , Estudos Retrospectivos , Registros Médicos/legislação & jurisprudência , Registros Médicos/normas , Inquéritos e Questionários , Taquicardia/complicações , Taquicardia/cirurgia
19.
Rev Esp Cardiol (Engl Ed) ; 66(12): 983-92, 2013 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-24774111

RESUMO

INTRODUCTION AND OBJECTIVES: This article presents the findings of the 2012 Spanish Catheter Ablation Registry. METHODS: Data were collected in 2 ways: retrospectively using a standardized questionnaire, and prospectively using a central database. Each participating center selected its own preferred method of data collection. RESULTS: Seventy-four Spanish centers voluntarily contributed data to the survey. A total of 11 042 ablation procedures were analyzed, averaging 149 (103) per center. The 3 main conditions treated were atrioventricular nodal reentrant tachycardia (n=2842; 25.7%), cavotricuspid isthmus (n=2485; 23%), and accessory pathways (n=1999; 18%). Atrial fibrillation was the fourth most common substrate treated (n=1852; 17%), representing a slight increase. The number of ventricular arrhythmia ablation procedures was similar to that of 2011, but there was a decrease in procedures for ventricular tachycardia associated with postinfarction scarring. The overall success rate was 94.9%, major complications occurred in 1.9%, and the overall mortality rate was 0.04%. CONCLUSIONS: Data from the 2012 registry show that the number of ablations performed continued to increase. Overall, they also show a high success rate and a low number of complications. Ablation of complex substrates continued to increase, particularly in the case of atrial fibrillation.


Assuntos
Arritmias Cardíacas/epidemiologia , Arritmias Cardíacas/cirurgia , Ablação por Cateter/estatística & dados numéricos , Sistema de Registros , Adulto , Idoso , Arritmias Cardíacas/diagnóstico , Fibrilação Atrial/diagnóstico , Fibrilação Atrial/epidemiologia , Fibrilação Atrial/cirurgia , Flutter Atrial/diagnóstico , Flutter Atrial/epidemiologia , Flutter Atrial/cirurgia , Ablação por Cateter/efeitos adversos , Ablação por Cateter/métodos , Criança , Eletrocardiografia/métodos , Feminino , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Prognóstico , Estudos Prospectivos , Estudos Retrospectivos , Medição de Risco , Índice de Gravidade de Doença , Sociedades Médicas , Espanha , Taquicardia por Reentrada no Nó Atrioventricular/diagnóstico , Taquicardia por Reentrada no Nó Atrioventricular/cirurgia , Taquicardia Ventricular/diagnóstico , Taquicardia Ventricular/epidemiologia , Taquicardia Ventricular/cirurgia , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA